The Biologics News and Reports Portal

Show Cart

La Merie Publishing

Results 81 - 100 of 189

Dec 2016 Report Package: Hot targets for empowered antibody and cell therapy technologies

1,140.00 €

1,900.00 €

(Discount: 40.00%)

Nov 2016 Flat-Rate Access to R&D Database & Reports from La Merie Publishing

7,000.00 €

Nov 2016 CD22: a suitable antigen for targeted payload delivery by immunotherapeutics

700.00 €

Oct 2016 Competitor Analysis: NGF-TrkA Pathway Agonists & Antagonists 2016

200.00 €

Sep 2016 Competitor Analysis Immunotoxins 2016

200.00 €

Sep 2016 Report package: T-Cell Immunotherapy by bispecific antibodies and CAR & TCR engineered T-cells

3,000.00 €

4,500.00 €

(Discount: 33.33%)

Aug 2016 CD123: a paradigmatic target for immunotherapeutic treatment modalities

700.00 €

Aug 2016 B-Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities

500.00 €

Aug 2016 TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies opens business opportunities beyond CD19 CARTs

2,450.00 €

Jun 2016 Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics 2016

250.00 €

Jun 2016 Therapeutic Antibody Reports Bundle: ADCs, Bispecifics, Biosimilars & Biosuperiors

3,100.00 €

6,200.00 €

(Discount: 50.00%)

Jun 2016 Competitor Analysis: Bispecific Antibodies for Cancer, Inflammatory & Other Diseases

500.00 €

May 2016 Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update

250.00 €

May 2016 Competitor Analysis: Biosimilar and Biosuperior Anti-Her2 Antibodies – 2016 Update

300.00 €

May 2016 Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies – 2016 Update

300.00 €

May 2016 Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies – 2016 Update

1,300.00 €

May 2016 Competitor Analysis: Biosimilar and Biosuperior Anti-TNF Antibodies – 2016 Update

500.00 €

May 2016 T-Cell Redirecting Bispecific Antibodies 2016: A competitive landscape analysis of stakeholders, technologies, pipelines and deals

2,050.00 €

Apr 2016 Competitor Analysis: CD19-Targeted Therapeutics - 2016 Update

300.00 €

Mar 2016 Blockbuster Biologics 2015: Sales of Recombinant Therapeutic Antibodies & Proteins

60.00 €

Shopping cart

Cart empty

Shopping cart

Cart empty

Latest report

Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

Featured Products

Report Package: “Drug the Undruggable” Technologies

RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

La Merie Publishing

Dec 2016 Report Package: Hot targets for empowered antibody and cell therapy technologies

Nov 2016 Flat-Rate Access to R&D Database & Reports from La Merie Publishing

Nov 2016 CD22: a suitable antigen for targeted payload delivery by immunotherapeutics

Oct 2016 Competitor Analysis: NGF-TrkA Pathway Agonists & Antagonists 2016

Sep 2016 Competitor Analysis Immunotoxins 2016

Sep 2016 Report package: T-Cell Immunotherapy by bispecific antibodies and CAR & TCR engineered T-cells

Aug 2016 CD123: a paradigmatic target for immunotherapeutic treatment modalities

Aug 2016 B-Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities

Aug 2016 TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies opens business opportunities beyond CD19 CARTs

Jun 2016 Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics 2016

Jun 2016 Therapeutic Antibody Reports Bundle: ADCs, Bispecifics, Biosimilars & Biosuperiors

Jun 2016 Competitor Analysis: Bispecific Antibodies for Cancer, Inflammatory & Other Diseases

May 2016 Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update

May 2016 Competitor Analysis: Biosimilar and Biosuperior Anti-Her2 Antibodies – 2016 Update

May 2016 Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies – 2016 Update

May 2016 Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies – 2016 Update

May 2016 Competitor Analysis: Biosimilar and Biosuperior Anti-TNF Antibodies – 2016 Update

May 2016 T-Cell Redirecting Bispecific Antibodies 2016: A competitive landscape analysis of stakeholders, technologies, pipelines and deals

Apr 2016 Competitor Analysis: CD19-Targeted Therapeutics - 2016 Update

Mar 2016 Blockbuster Biologics 2015: Sales of Recombinant Therapeutic Antibodies & Proteins

Shopping cart

Latest report

Featured Products

Latest Target Pipeline

Shopping cart

Latest report

Featured Products

Latest Target Pipeline

La Merie Biologics

FREE Weekly News Bulletin

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing